文献速递妇科

晚期卵巢癌初次减瘤手术后至化疗开始时间对生存的影响:一项基于全国人群的SweGCG研究

Has time to chemotherapy from primary debulking surgery in advanced ovarian cancer an impact on survival? - A population-based nationwide SweGCG study.
PubMed 文献 · Gynecol Oncol · 2024-04-10

该研究基于瑞典妇科癌症质量登记库2008至2018年数据,纳入1694例FIGO IIIC-IV期上皮性卵巢/输卵管/原发腹膜癌患者,分析初次减瘤手术后至化疗开始时间(TTC)对相对生存的影响。全队列5年相对生存率为37.9%,TTC各组间无差异;但在无残留病灶(R0)队列中,TTC≤21天和22-28天的2年相对生存率高于TTC>42天。

要点

  • 全队列5年相对生存率为37.9%,TTC分组间无差异。
  • R0队列中TTC≤21天和22-28天2年相对生存率分别为91.6%和91.4%,高于TTC>42天的79.1%。
  • R0队列中TTC>42天、FIGO IV期和非浆液性组织学与2年超额死亡率升高相关。

核心结论

  • 全队列中,FIGO IV期、非浆液性形态和残留病灶影响5年相对生存,而TTC不影响。
  • 在初次减瘤手术后无残留病灶的患者中,较长的TTC与较差的2年生存相关。

研究设计与样本

  • 基于瑞典妇科癌症质量登记库的全国人群研究,纳入2008至2018年注册的FIGO IIIC-IV期上皮性卵巢/输卵管/原发腹膜癌女性,均接受初次减瘤手术和化疗,共1694例,中位年龄65.0岁。
  • TTC分为≤21天、22-28天、29-35天、36-42天和>42天五组。
  • 采用Pohar-Perme净生存估计法计算相对生存,采用泊松回归模型估计超额死亡率比(EMRR)。

主要发现

  • 全队列5年相对生存率为37.9%,TTC各组间无差异。
  • R0队列(n=806)中,TTC≤21天组2年相对生存率为91.6%,22-28天组为91.4%,均高于TTC>42天组的79.1%。
  • R0队列中,与TTC 0-21天相比,TTC>42天(EMRR 2.33,p=0.026)、FIGO IV期(EMRR 1.83,p=0.007)和非浆液性组织学(EMRR 4.20,p<0.001)与2年超额死亡率升高相关。
  • R0队列中,TTC与2年生存的关联见于FIGO IV期,但未见见于IIIC期。
  • 有残留病灶的患者中,TTC与相对生存无关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The aim of the study was to investigate if time to start chemotherapy (TTC) after primary debulking surgery (PDS) impacted relative survival (RS) in advanced epithelial ovarian/fallopian tube/primary peritoneal cancer (EOC). METHODS: Nationwide population-based study of women with EOC FIGO stages IIIC-IV, registered 2008-2018 in the Swedish Quality Register for Gynecologic Cancer, treated with PDS and chemotherapy. TTC was categorized into; ≤21 days, 22-28 days, 29-35 days, 36-42 days and > 42 days. Relative survival (RS) was estimated using the Pohar-Perme estimate of net survival. Multivariable analyses of excess mortality rate ratios (EMRRs) were estimated by Poisson regression models. RESULTS: In total, 1694 women were included. The median age was 65.0 years. Older age and no residual disease were more common in TTC >42 days than 0-21 days. The RS at 5-years was 37.9% and did not differ between TTC groups. In the R0 (no residual disease) cohort (n = 806), 2-year RS was higher in TTC ≤21 days (91.6%) and 22-28 days (91.4%) than TTC >42 days (79.1%). TTC >42 days (EMRR 2.33, p = 0.026), FIGO stage IV (EMRR 1.83, p = 0.007) and non-serous histology (EMRR 4.20, p < 0.001) were associated with 2-year worse excess mortality compared to TTC 0-21 days, in the R0 cohort. TTC was associated with 2-year survival in the R0 cohort in FIGO stage IV but not in stage IIIC. TTC was not associated with RS in patients with residual disease. CONCLUSIONS: For the entire cohort, stage IV, non-serous morphology and residual disease, but not TTC, influenced 5-year relative survival. However, longer TTC was associated with a poorer 2-year survival for those without residual disease after PDS.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Dahm-Kähler P, Rådestad AF, Holmberg E, et al. Has time to chemotherapy from primary debulking surgery in advanced ovarian cancer an impact on survival? - A population-based nationwide SweGCG study. Gynecol Oncol. 2024. PMID: 38603954. doi:10.1016/j.ygyno.2024.03.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。